June 23, 2017 07:30 AM Eastern Daylight Time

BUSINESS WIRE

Samsung Bioepis' Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency

Opens in new window

Download

Full Size JPEG, 1270x458, 113.5 KB
Small JPEG, 480x173, 44.3 KB
Preview JPEG, 144x52, 14.6 KB
Thumbnail JPEG, 120x43, 13.5 KB

Smart Multimedia Gallery

Samsung Bioepis headquarters in Incheon, Korea. (Photo: Business Wire)

Samsung Bioepis headquarters in Incheon, Korea. (Photo: Business Wire)

View and Share Photo

Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)

Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)

View and Share Photo

Engineer at the Samsung Bioepis R&D Center. (Photo: Business Wire)

Engineer at the Samsung Bioepis R&D Center. (Photo: Business Wire)

View and Share Photo

Engineers at the Samsung Bioepis R&D Center. (Photo: Business Wire)

Engineers at the Samsung Bioepis R&D Center. (Photo: Business Wire)

View and Share Photo

http://www.businesswire.it/multimedia/it/20170623005242/en/4105677/Samsung-Bioepis-Imraldi%C2%AE-Adalimumab-Recommended-for-Approval-by-European-Medicines-Agency

Share

Email

All News | News with Multimedia > Press Release: Samsung Bioepis' Imraldi® (Adalimumab) Recommen...